Primary Biliary Cirrhosis. Therapeutic Advances.

Frank Czul, Adam L Peyton, Cynthia Levy

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease characterized by destruction of the interlobular bile ducts, which, if untreated, leads to fibrosis, biliary cirrhosis, and liver failure. Because liver transplantation remains the only curative option for PBC, the goals of treatment are to slow the rate of progression, to alleviate related symptoms, and to prevent complications. Ursodeoxycholic acid is the only US Food and Drug Administration-approved medical treatment of PBC. Several agents are undergoing evaluation as monotherapy or as an adjuvant to ursodeoxycholic acid. This review summarizes current therapeutic advances in the care of patients with PBC.

Original languageEnglish (US)
Pages (from-to)229-242
Number of pages14
JournalClinics in liver disease
Issue number2
StatePublished - May 1 2013


  • 6α-Ethyl-chenodeoxycholic acid
  • Fibrates
  • Primary biliary cirrhosis
  • Therapeutics
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Primary Biliary Cirrhosis. Therapeutic Advances.'. Together they form a unique fingerprint.

Cite this